Jefferies Financial Group Reaffirms Buy Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating restated by equities research analysts at Jefferies Financial Group in a research note issued to investors on Tuesday, Digital Look reports. They presently have a GBX 2,500 price objective on the stock. Jefferies Financial Group‘s price objective suggests a potential upside of 32.00% from the stock’s current price.

A number of other analysts have also recently issued reports on GSK. Berenberg Bank boosted their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research report on Tuesday, September 15th. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,975 target price on shares of GSK in a research report on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research report on Tuesday, September 29th. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of GBX 2,064.38.

GSK Stock Down 1.0%

Shares of LON GSK traded down GBX 20 during trading hours on Tuesday, hitting GBX 1,894. The stock had a trading volume of 6,173,946 shares, compared to its average volume of 12,407,307. The firm’s 50-day moving average price is GBX 1,847.39 and its two-hundred day moving average price is GBX 1,918.60. GSK has a 52 week low of GBX 1,592 and a 52 week high of GBX 2,282. The company has a market capitalization of £75.89 billion, a P/E ratio of 16.08, a P/E/G ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82.

GSK (LON:GSK) last announced its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Analysts anticipate that GSK will post 175.98 EPS for the current fiscal year.

Insider Activity at GSK

In other GSK news, insider Anne Beal purchased 637 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was purchased at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction dated Friday, September 18th. The stock was bought at an average price of GBX 1,881 per share, with a total value of £28,215. Over the last 90 days, insiders have acquired 2,151 shares of company stock valued at $6,021,921. Company insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.